Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
Hong Kong Med J ; 14 Suppl 4: 36-8, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18708673

ABSTRACT

1. We have demonstrated for the first time that the helicase of a ribonucleic acid virus, the SARS coronavirus (SARS-CoV), is a valid target for drug development. 2. Using high throughput screen and chemical synthesis, several lead compounds targeting the SARS-CoV helicase have been identified. We have shown that these compounds can inhibit SARS-CoV helicase activity and viral growth in cell culture systems. These compounds can potentially be used to target other viruses.


Subject(s)
DNA Helicases/pharmacology , Severe Acute Respiratory Syndrome/drug therapy , Severe acute respiratory syndrome-related coronavirus/drug effects , Virus Replication/drug effects , Animals , Antiviral Agents/pharmacology , Cells, Cultured , Chlorocebus aethiops , DNA Helicases/genetics , Drug Delivery Systems , Drug Evaluation, Preclinical , Severe acute respiratory syndrome-related coronavirus/genetics , Sensitivity and Specificity , Severe Acute Respiratory Syndrome/genetics , Severe Acute Respiratory Syndrome/virology , Vero Cells/cytology , Vero Cells/drug effects , Virus Replication/genetics
SELECTION OF CITATIONS
SEARCH DETAIL